Therefore, here we analyzed BC models with diverse genomic backgrounds and acquired palbociclib resistance by single-cell RNA sequencing (scRNA-seq) in order to dissect the impact of transcriptional heterogeneity to CDK4/6i resistance in luminal BC. This evidence concerns the gene CDK4 and breast cancer.